Quick Answer
Relay Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $15.36 million for the year ending 2025.
- Relay Therapeutics, Inc. showed an increase of +53.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Relay Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 81.4%.
- Historical annual values: Fiscal year 2025: $15.36 million | Fiscal year 2024: $10.01 million | Fiscal year 2023: $25.55 million | Fiscal year 2022: $1.38 million | Fiscal year 2021: $3.03 million | Fiscal year 2020: $82.65 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: